10 Years of Alzheimer's Research & Therapy
Thematic Series
Call for Papers - Open Collections
Announcing the launch of In Review
In partnership with Research Square, Alzheimer's Research & Therapy is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Read more about the full range of benefits of In Review and how to opt in, or see the In Review platform for yourself here.
Articles
-
-
Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease
-
Age-dependent emergence of neurophysiological and behavioral abnormalities in progranulin-deficient mice
-
Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer’s disease
-
Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Thematic Series - Subject Cognitive Decline
Target populations for early diagnosis, disease course prediction and interventions in Alzheimer’s disease are a major focus of current research. Subjective cognitive decline (SCD) has emerged as a pre-mild cognitive impairment (pre-MCI) at risk condition of dementia and cognitive decline.
Read our new thematic series, guest edited by José Luis Molinuevo, Frank Jessen & Wiesje Van der Flier
Alzheimer's blogs from BMC
Advertisement
Affiliated with
-
Alzheimer's Research & Therapy is affiliated with Alzheimer's Disease International (ADI), London, United Kingdom.
Annual Journal Metrics
-
Speed
55 days to first decision for reviewed manuscripts only
40 days to first decision for all manuscripts
133 days from submission to acceptance
31 days from acceptance to publication
Citation Impact
6.142 - 2-year Impact Factor
7.072 - 5-year Impact Factor
1.601 - Source Normalized Impact per Paper (SNIP)
2.404 - SCImago Journal Rank (SJR)
Usage
522,695 downloads
937 Altmetric mentions
Advertisement
